nach oben

Current Diabetes Reports

Erschienen in:

01.01.2019 | Economics and Policy in Diabetes (AA Baig and N Laiteerapong, Section Editors)

Economic Impact of Diabetes in Japan

verfasst von: Tatsuhiko Urakami, Remi Kuwabara, Kei Yoshida

Erschienen in: Current Diabetes Reports | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of review

The economic burden of diabetes in Japan is already serious and will become greater in the future. We review the economic impact of diabetes in Japan to examine viable options for mitigating its effects.

Recent findings

Medical costs for diabetes have been increasing by US $1 million annually, reaching US $11 million in 2009, of which US $7 million was accounted for by people aged 65 years or older. The quality of treatment of diabetes in Japan is higher than in other regions in the world. This can be more effective for achieving glycemic control, but is also more expensive compared with conventional treatment.

Summary

Because of the high cost of diabetes in Japan, a coordinated response is needed. Intervention trials for people with prediabetes aimed at preventing the occurrence of diabetes seem to be the most cost-effective method for lowering the medical costs of diabetes, rather than the use of new, expensive antidiabetic drugs in patients with established diabetes.

International Diabetes Federation, editor. Diabetes Atlas. 6th ed: International Diabetes Federation; 2013.

• Health and Welfare Statistics Association. Kokumin Eisei no Doko (Trends in Nation’s Health, Japan). Health and Welfare Statistics Association: Tokyo; 2015 (in Japanese). This study provides annual national health trends in Japan.

Bommer C, Heesemann E, Sagalova V, Manne-Goehler J, Atun R, Bärnighausen T, et al. The global economic burden of diabetes in adults aged 20-79 years: a cost-off-illness study. Lancet Diabetes Endocrinol. 2017;5:423–30.CrossRef

Sagel JE. Cost-off-illness studies-A primer, RTI-UNC Center of Excellence in Health Promotion Economics; 2006.

Bagust A, Hopkinson PK, Maslove L, Currie CI. The project health care burden of type 2 diabetes in the UK from 2000 to 2060. Diabet Med. 2002;19(Suppl. 4):1–5.CrossRef

Huang ES, Basu A, O’Grady M, Capretta JC. Projecting the future diabetes population size and related costs for the U.S. Diabetes Care. 2009;32:2225–9.CrossRef

Vos T, Gross J, Begg S, Mann N. Projection of health care expenditure by disease: a case study from Australia. Brisbane, Australia: School of population Health, University of Queensland; 2007.

Waldeyer R, Brinks R, Rathmann W, Glani G, Icks A. Projection of the burden of type 2 diabetes mellitus in Germany: a demographic modelling approach to estimate the direct medical excess costs from 2010 to 2040. Diabet Med. 2013;30:999–1008.CrossRef

Hex N, Bartlett C, Wright D, Taylor M, Varley D. Estimating the current and future costs of type 1 and type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med. 2012;29:855–62.CrossRef

10.

Javanbakht M, Mashayekhi A, Baradaran HR, Haghdoost A, Afshin A. Projection of diabetes population size and associated economic burden through 2030 in Iran: evidence from micro-simulation Markov model and Bayesian meta-analysis. PLoS One. 2015;10:e0132505.CrossRef

11.

Rowley WR, Bezold C. Creating public awareness: state 2025 diabetes forecasts. Popul Health Manag. 2012;15:194–200.CrossRef

12.

• Seuring T, Archangelidi O, Suhrcke. The economic costs of type 2 diabetes: A global systemic review. Pharmacoeconomics. 2015;33:811–31 This study reviews the societal cost of type 2 diabetes worldwide, estimated using direct and indirect costs based on previously published literature.CrossRef

13.

•• Bommer C, Sagalova V, Heesemann E, Manne-Goehler J, Atun R, Bärnighausen T, et al. Global economic burden of diabetes in adults: projections from 2015 to 2030. Diabetes Care. 2018;41:963–70 This study reports the GDP-relative economic burden in individuals aged 20–79 years using epidemiological and demographic data in 184 countries, projected from 2015 for 2030.CrossRef

14.

Health and Welfare Statistics Association. Kokumin Eisei no Doko (Trends in Nation’s Health, Japan). Tokyo: Health and Welfare Statistics Association; 2001. (in Japanese)

15.

Kuriyama S, Tsuji I, Ohkubo T, Anzai Y, Takahashi K, Watanaeb Y, et al. Medical care expenditure associated with body mass index in Japan: the Ohsaki Study. Int J Obes Relat Metab Disord. 2002;26:1069–74.CrossRef

16.

Nakamura K, Okamura T, Kanda H, Hayakawa T, Okayama A, Ueshima H, et al. Medical costs of obese Japanese: a 10-year follow-up study of National Health Insurance in Shiga, Japan. Eur J Pub Health. 2007;17:424–9.CrossRef

17.

Shimoda M, Kaku K. Medical economy in the treatment of diabetes and its problems. Nippon Rinsho. 2012;70(Suppl. 5):663–6 (in Japanese).PubMed

18.

Inada O. Medical costs in type 2 diabetes. Himan to Tounyobyo. 2009;8:672–5 (in Japanese).

19.

DCCT Research Group. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. J Pediatr. 1994;125:177–88.CrossRef

20.

The Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes. 1995;44:968–83.CrossRef

21.

Maruyama T. Medical costs in type 1 diabetes. Himan to Tounyobyo. 2009;8:670–1 (in Japanese).

22.

• Kikuchi N, Tajima N, Ueki K, Yokoyama T, Ikegami H, Urakami T. Definition of complete insulin -dependent type 1 diabetes. Report of research grant from Ministry of Health, Labor and Welfare (H28-Junkanki-Ippan-006), 2018 (in Japanese). This report discusses the current economic status of diabetes treatment and management in 2018.

23.

Aono S, Matsuura N, Ameiya S, Igrashi Y, Uchigata Y, Urakami T, et al. Epidemiological survey of social adjustment and living condition in patients with childhood onset insulin-dependent diabetes mellitus aged over 18 years. Tounyobyo. 1997;40:547–55 (in Japanese).

24.

Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.CrossRef

25.

Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20:537–44.CrossRef

26.

Hisashige A. Prevention of diabetes and economic efficacy. Prog Med. 2005;25:80–5 (in Japanese).

Titel: Economic Impact of Diabetes in Japan
verfasst von: Tatsuhiko Urakami
Remi Kuwabara
Kei Yoshida
Publikationsdatum: 01.01.2019
Verlag: Springer US
Erschienen in: Current Diabetes Reports / Ausgabe 1/2019
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI: https://doi.org/10.1007/s11892-019-1122-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Restriktion auf vier Wochen Therapie bei Schlaflosigkeit ist absurd!“

06.05.2024 Insomnie Nachrichten

Chronische Insomnie als eigenständiges Krankheitsbild ernst nehmen und adäquat nach dem aktuellen Forschungsstand behandeln: Das forderte der Schlafmediziner Dr. Dieter Kunz von der Berliner Charité beim Praxis Update.

GLP-1-Rezeptoragonisten und SGLT-2-Hemmer: zusammen besser

06.05.2024 Typ-2-Diabetes Nachrichten

Immer häufiger wird ein Typ-2-Diabetes sowohl mit einem GLP-1-Rezeptor-Agonisten als auch mit einem SGLT-2-Inhibitor behandelt. Wie sich das verglichen mit den Einzeltherapien auf kardiovaskuläre und renale Komplikationen auswirkt, wurde anhand von Praxisdaten aus Großbritannien untersucht.

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

06.05.2024 Kolonkarzinom Nachrichten

Menschen mit linksseitigem Kolonkarzinom leben im Mittel zweieinhalb Jahre länger als solche mit rechtsseitigem Tumor. Auch aktuell ist das Sterberisiko bei linksseitigen Tumoren US-Daten zufolge etwa um 11% geringer als bei rechtsseitigen.

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen